Structured intelligence coverage

Structured records are temporarily unavailable. The published profile and its source ledger remain accessible.

Identity checks do not refresh the age of governance evidence. Open a record for its source date and review state.

Profile

Identity, professional record and current appointments.

Overview

Professional record at a glance

A concise summary of information supported by the cited public sources. Missing information is treated as unknown, not as a negative finding.

Current roles
22 current organizations shown on this profile
Board positions
22 supported by public sources, 0 supplied by the profile owner
Committee roles
4Roles supported by the sources cited on this profile
Qualifications
Not establishedNo qualification is currently confirmed by the cited sources

Professional narrative

About

Mr. Enyedy is former President and CEO of ImmunoGen (acquired by AbbVie in 2024). He has more than three decades of combined general management, business development, and legal experience in biotechnology. He previously served as CEO of Proteostasis Therapeutics and held diverse roles at Genzyme and Shire.

Sources are shown with the information they support.

Current roles

Appointments & responsibilities

Board appointments

Governance

Board appointments, committee responsibilities and disclosed relationships.

Committee appointments across companies · Temporarily unavailable

Structured records for this section are unavailable. This does not establish that no records exist. Published profile sources remain in Evidence & History.

Board and advisory record

Board service

Sources are shown with each role, education record, or credential.

Independent Director

Charles River Laboratories

2025-01-01 · current

Confirmed by public sourceView source

Director

BIOMARIN PHARMACEUTICAL INC

2023-01-01 · current

Confirmed by public sourceView source

Connections

Explore the roles, education and affiliations published in this record.

BIOMARIN PHARMACEUTICAL INC

Open BIOMARIN PHARMACEUTICAL INC profile →

Director at BIOMARIN PHARMACEUTICAL INC

2023-01-01 → End not stated

current · source reported

Observed: 2026-09-25

BIOMARIN PHARMACEU…BIOMARIN PHARMACEUTICAL INCCharles River Labo…Charles River LaboratoriesMark Enyedy

Dashed lines mark past roles. Select a connection to see its dates and sources.

Relationship map

Connected through the public record

Direct relationships from verified facts and published résumé records. Private connections are excluded.

Direct public links only

Only published affiliations are shown here. Private relationships require authorized access.

Experience

Career history, education, credentials and public contributions.

Published record

Featured coverage

Selected publications and public sources used to establish this profile. Inclusion records provenance; it is not an endorsement.

Source 1 · Sec FilingBMRN DEF 14A director slateSupports Board role, Committee assignments.Open sourceSource 2 · Sec FilingCRL DEF 14A director slateSupports AI and ML experience, Board role, Committee assignments, Cybersecurity experience, Technology background.Open source

Basis

Identifiers, sources, dates and record limitations.

Identifiers

Alpha ID
alpha:person:mark-enyedy
Record version
public-0

Published evidence records

6 evidence records, matching Agent View. Records may refer to different locations or observations in the same document. This count is not a count of independent corroborating sources.

  1. BMRN DEF 14A director slate

    sec filing · Source published: Apr 21, 2026 · Retrieved: May 7, 2026

    Supports 2 claims
    • Board role: Board role: Director · Claim reviewed: May 16, 2026
    • Committee assignments: Committee assignments: Nominating/Governance, Transactions and Strategy · Claim reviewed: May 7, 2026

  2. Open source

    sec proxy · Source published: Apr 21, 2026 · Retrieved: May 7, 2026

    Supports 1 claim
    • Professional Role: Director at BIOMARIN PHARMACEUTICAL INC · Claim reviewed: May 16, 2026

  3. CRL DEF 14A director slate

    sec filing · Source published: Mar 31, 2026 · Retrieved: May 16, 2026

    Supports 5 claims
    • AI and ML experience: AI and ML experience: not identified in the cited filing · Claim reviewed: May 16, 2026
    • Board role: Board role: Director · Claim reviewed: May 16, 2026
    • Committee assignments: Committee assignments: Corporate Governance and Nominating, Strategic Planning and Capital Allocation · Claim reviewed: May 16, 2026
    • Cybersecurity experience: Cybersecurity experience: not identified in the cited filing · Claim reviewed: May 16, 2026
    • Technology background: Technology background: not identified in the cited filing · Claim reviewed: May 16, 2026

  4. Open source

    sec proxy · Source published: Mar 31, 2026 · Retrieved: May 3, 2026

    Supports 1 claim
    • Professional Role: Independent Director at Charles River Laboratories · Claim reviewed: May 16, 2026

  5. Open source

    public source · Source published: Date unavailable · Retrieved: Date unavailable

    Supports 1 claim
    • Board membership: Serves on the board of Charles River Laboratories · Claim reviewed: May 16, 2026

  6. Open source

    public source · Source published: Date unavailable · Retrieved: Date unavailable

    Supports 1 claim
    • Board membership: Serves on the board of BIOMARIN PHARMACEUTICAL INC · Claim reviewed: May 16, 2026

Sources

Sources and published information

Each item links to the public source used to support it. When sources disagree, the item is clearly marked for review.

AI and ML experience · Source reportedAI and ML experience: not identified in the cited filing1 source
Verification
Source reported
Confidence
72%
Last reviewed
May 16, 2026
  • SEC EDGAR

    Sec Filing · Tier 3 · Reviewed May 16, 2026

Board membership · Source reportedServes on the board of BIOMARIN PHARMACEUTICAL INC1 source
Verification
Source reported
Confidence
Not stated
Last reviewed
Not stated
Board membership · Source reportedServes on the board of Charles River Laboratories1 source
Verification
Source reported
Confidence
Not stated
Last reviewed
Not stated
Board role · CorroboratedBoard role: DirectorSupported by 2 public records2 sources
Verification
Corroborated
Confidence
92%
Last reviewed
May 16, 2026
  • SEC EDGAR

    Sec Filing · Tier 3 · Reviewed May 7, 2026

  • SEC EDGAR

    Sec Filing · Tier 3 · Reviewed May 16, 2026

Committee assignments · Source reportedCommittee assignments: Corporate Governance and Nominating, Strategic Planning and Capital Allocation1 source
Verification
Source reported
Confidence
88%
Last reviewed
May 16, 2026
  • SEC EDGAR

    Sec Filing · Tier 3 · Reviewed May 16, 2026

Committee assignments · Source reportedCommittee assignments: Nominating/Governance, Transactions and Strategy1 source
Verification
Source reported
Confidence
88%
Last reviewed
May 7, 2026
  • SEC EDGAR

    Sec Filing · Tier 3 · Reviewed May 7, 2026

Cybersecurity experience · Source reportedCybersecurity experience: not identified in the cited filing1 source
Verification
Source reported
Confidence
72%
Last reviewed
May 16, 2026
  • SEC EDGAR

    Sec Filing · Tier 3 · Reviewed May 16, 2026

Technology background · Source reportedTechnology background: not identified in the cited filing1 source
Verification
Source reported
Confidence
72%
Last reviewed
May 16, 2026
  • SEC EDGAR

    Sec Filing · Tier 3 · Reviewed May 16, 2026

View all sources6 records
  1. SEC EDGAR

    Sec Filing · Tier 3 · Reviewed May 7, 2026

    Supports: Board role · Committee assignments

  2. https://www.sec.gov/Archives/edgar/data/1048477/000162828026026290/bmrn-20260421.htm

    Sec Proxy · Tier not stated · Reviewed May 7, 2026

    Supports: Director at BIOMARIN PHARMACEUTICAL INC (NASDAQ: BMRN)

  3. SEC EDGAR

    Sec Filing · Tier 3 · Reviewed May 16, 2026

    Supports: AI and ML experience · Board role · Committee assignments · Cybersecurity experience · Technology background

  4. https://www.sec.gov/Archives/edgar/data/1100682/000110465926037367/tm261421-1_def14a.htm

    Sec Proxy · Tier not stated · Reviewed May 3, 2026

    Supports: Independent Director at Charles River Laboratories (NYSE: CRL)

  5. https://www.sec.gov/Archives/edgar/data/1100682/000110465926037367/tm261421-1_def14a.htm

    Public Source · Tier not stated · Reviewed Not stated

    Supports: Board membership

  6. https://www.sec.gov/Archives/edgar/data/1048477/000162828026026290/bmrn-20260421.htm

    Public Source · Tier not stated · Reviewed Not stated

    Supports: Board membership